Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Licenses Gene Targeting Tech to Aventis

NEW YORK, April 22 - Lexicon Genetics said today it has non-exclusively licensed rights to its gene targeting technologies to Aventis, for use in the pharmaceutical company's internal research.


Lexicon, of The Woodlands, Texas, uses gene knockout technology in mammals to discovery gene function and utility of genes. It holds patents on these technologies.


The company did not disclose the financial terms of the agreement.


Pfizer, GlaxoSmithKline, Merck, and Millennium Pharmaceuticals are among the other licensees of Lexicon's technology.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.